Research Article
Analysis of the Distribution and Antibiotic Resistance of Pathogens Causing Infections in Hospitals from 2017 to 2019
Table 10
Drug resistance rates of Pseudomonas aeruginosa from 2017 to 2019.
| | 2017 | 2018 | 2019 | Drugs | Drug resistance rate (%) | Drugs | Drug resistance rate (%) | Drugs | Drug resistance rate (%) |
| Pseudomonas aeruginosa | Aztreonam | 37.2 | Meropenem | 22 | Meropenem | 18.4 | | Cefepime | 34 | Aztreonam | 18.8 | Imipenem | 15.8 | | Imipenem | 33.5 | Levofloxacin | 18.8 | Levofloxacin | 13.7 | | Piperacillin | 29.1 | Cefepime | 18.7 | Aztreonam | 13.4 | | Meropenem | 27.1 | Imipenem | 18.2 | Gentamicin | 12.2 | | Gentamicin | 25.2 | Gentamicin | 15.6 | Cefepime | 12.1 | | Piperacillin-sulbactam | 25.1 | Ciprofloxacin | 13.5 | Piperacillin | 11.6 | | Ceftazidime | 23.7 | Piperacillin | 12.8 | Cefoperazone-sulbactam | 9.2 | | Levofloxacin | 20 | Ceftazidime | 12.2 | Ciprofloxacin | 8.6 | | Ciprofloxacin | 18.4 | Cefoperazone-sulbactam | 11.1 | Tobramycin | 7.7 | | Tobramycin | 13.5 | Tobramycin | 9.9 | Piperacillin-tazobactam | 7.2 | | Amikacin | 10 | Amikacin | 9.2 | Ceftazidime | 6.8 | | Polymyxin B | 2.5 | Piperacillin-tazobactam | 8.6 | Amikacin | 3.5 | | | | Polymyxin B | 0 | Polymyxin B | 0.0 |
|
|